SRR8518427
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- GLYCOLYSIS+0.230
- APICAL_JUNCTION+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.190
- NOTCH_SIGNALING+0.180
- APICAL_SURFACE+0.150
- TGF_BETA_SIGNALING+0.130
- MTORC1_SIGNALING+0.120
- MYOGENESIS+0.120
- UV_RESPONSE_DN+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.380
- MYC_TARGETS_V2-0.350
- IL6_JAK_STAT3_SIGNALING-0.330
- E2F_TARGETS-0.280
- DNA_REPAIR-0.250
- INFLAMMATORY_RESPONSE-0.250
- TNFA_SIGNALING_VIA_NFKB-0.250
- COMPLEMENT-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 48155bad-7de9-401d-a495-972cbbb8f276 | — | — | 0.768 |
| 2 | 20070115.Her2HRneg | — | E | 0.760 |
| 3 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.754 |
| 4 | SRR8518172 | — | E | 0.749 |
| 5 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.745 |
| 6 | 20030017.LumA | — | B | 0.741 |
| 7 | TCGA-CV-7406-01A-11R-2081-07 | — | — | 0.732 |
| 8 | TCGA-A8-A093-01A-11R-A00Z-07 | — | B | 0.730 |
| 9 | TCGA-D8-A27P-01A-11R-A16F-07 | — | B | 0.730 |
| 10 | TCGA-BH-A0HQ-01A-11R-A034-07 | — | B | 0.728 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |